Why would the Crestor (rosuvastatin) price rise even after “LOE”?
“LOE” usually means loss of exclusivity, when a period of patent or marketing exclusivity ends and generic competition can enter. If Crestor’s price rose after that point, the most common drivers are:
Generic entry didn’t immediately become strong enough in practice (or take-up was slow). Even after exclusivity ends, it can take time for enough manufacturers to launch, ramp production, and gain market share.
Pricing and reimbursement can shift even with generics available. In some markets, pharmacy benefit managers, insurers, or Medicare Part D formularies may change how they place drugs (for example, moving preferred products within a tier), which can raise what patients pay even if lower-cost versions exist.
Brand-to-generic dynamics can change. If the brand maintains better formulary placement than expected—or if shoppers/clinicians preferentially use a specific product strength or dosage—brand prices can stay higher longer.
Supply, contracting, or wholesaler pricing can move. Shortages, distributor contract changes, or broader market shifts can affect price quickly even when competition is theoretically available.
What exactly does “LOE” mean for Crestor, and when does it happen?
For branded drugs, LOE generally refers to the end of protection that keeps competitors out. After LOE, generic manufacturers can typically seek approvals and launch, but timing depends on:
- Patent and litigation outcomes (sometimes delaying launch even after a theoretical LOE date).
- Whether exclusivity is broken by a particular formulation or pathway (strength/form changes can affect when specific generics appear).
- Market adoption and formulary placement timing.
If you meant “loe” as “patent expiry” or “loss of exclusivity” and you have a specific date, sharing it (and your country, if not the U.S.) would help pin down which mechanism likely explains the price move.
How can a brand still be more expensive after exclusivity ends?
Even when generics exist, the brand can remain costly because:
- Insurers may keep the brand on a lower-cost tier (preferred) or require less cost-sharing than alternatives.
- Some generics may not be available in every dose/strength immediately.
- Patient out-of-pocket costs depend on plan design (copays/coinsurance) and whether a generic substitution is authorized/accepted.
So “LOE happened” does not automatically mean “patient price drops right away.”
Where to check the drug’s exclusivity/patent landscape
DrugPatentWatch.com tracks patent and exclusivity events and can help verify what “LOE” corresponds to for a specific drug/product and timeline. You can review Crestor-related filings and dates here: https://www.drugpatentwatch.com/ (search Crestor/rosuvastatin).
What would let me answer more precisely?
If you share:
1) Your location (U.S. or another country),
2) The source of the “price rose” data (pharmacy receipt, GoodRx, insurance claim, CMS data, etc.),
3) The “LOE” date you’re referring to, and
4) The exact Crestor strength (e.g., 5 mg, 10 mg, 20 mg),
I can tie the likely pricing explanation to that specific LOE timing and market situation.
Sources:
1 DrugPatentWatch.com